BDTX
NASDAQ · Biotechnology
Black Diamond Therapeutics I
$1.83
-0.05 (-2.66%)
Financial Highlights (FY 2026)
Revenue
69.50M
Net Income
22.21M
Gross Margin
—
Profit Margin
32.0%
Rev Growth
—
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | 44.4% | 44.4% | 44.4% |
| Operating Margin | 17.9% | 11.6% | 9.3% | 10.8% |
| Profit Margin | 32.0% | 7.8% | 10.3% | 9.4% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 69.50M | 26.85M | 24.30M | 27.99M |
| Gross Profit | — | 11.92M | 10.79M | 12.43M |
| Operating Income | 12.43M | 3.13M | 2.26M | 3.04M |
| Net Income | 22.21M | 2.09M | 2.49M | 2.63M |
| Gross Margin | — | 44.4% | 44.4% | 44.4% |
| Operating Margin | 17.9% | 11.6% | 9.3% | 10.8% |
| Profit Margin | 32.0% | 7.8% | 10.3% | 9.4% |
| Rev Growth | — | +10.3% | +9.4% | -7.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 36.97M | 36.00M | 39.74M |
| Total Equity | — | 91.17M | 103.86M | 92.20M |
| D/E Ratio | — | 0.41 | 0.35 | 0.43 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 12.76M | 3.87M | 3.57M | 4.44M |
| Free Cash Flow | — | 2.98M | 2.09M | 2.99M |